Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab adizutecan in MET-amplified advanced solid tumors
2024-518871-74-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of telisotuzumab adizutecan in Nonhematologic neoplasms, sponsored by AbbVie Inc. Primary endpoint: Confirmed objective response. Planned start Jun 2026; status: authorised.
02
Drugs
telisotuzumab adizutecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-518871-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518871-74-00.